A new study has examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than ...
In a pooled analysis of clinical trial data on diabetic patients at high cardiovascular risk or with chronic kidney disease, canagliflozin demonstrated consistent benefits across the spectrum of age ...